InspireMD Q2 EPS $(0.24) Beats $(0.30) Estimate, Sales $1.65M Beat $1.55M Estimate
Portfolio Pulse from Benzinga Newsdesk
InspireMD reported Q2 losses of $(0.24) per share, beating the analyst consensus estimate of $(0.30) by 20%. The company also reported quarterly sales of $1.65 million, beating the analyst consensus estimate of $1.55 million by 6.39%. This represents a 59.32% increase in losses and a 7.71% increase in sales from the same period last year.
August 08, 2023 | 11:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
InspireMD's Q2 results exceeded analyst estimates, with a 20% better EPS and a 6.39% higher sales figure.
InspireMD's better-than-expected Q2 results could lead to a positive short-term impact on its stock price. The company's losses were less than anticipated and sales were higher, which are positive indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100